Background: After the A/H1N1 influenza pandemic in 2009, two new drugs against
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TOCHINO eT al. was in the previous season, but the improvements in symptoms were similar between the four neuraminidase inhibitors during the 2011-2012 season. 2 Clinics and hospitals are usually very busy during the winter season because there are typically many patients with viral infections, cardiovascular disease, or respiratory disease in addition to influenza.
Therefore, time for a detailed investigation during the winter season is limited, which prompted us to conduct a less time-intensive selfreported survey via a postcard questionnaire for influenza. These postcard-based studies collected data regarding demographic characteristics, flu vaccination status, symptoms, prescribed medications, and drug-related adverse events. This survey was initially conducted during the 2010-2011 season, and the results were previously reported in a Japanese journal. 1 The second study was conducted using the same method during the 2011-2012 season and also reported in another Japanese journal. 2 Our studies are considered to be very useful for clinicians on primary care, because our studies are widely practiced in about 50 hospitals and clinics. The third study was conducted during the 2012-2013 season to investigate the current usage and effectiveness of influenza medications and factors related to the time taken to alleviate fever. We report here the complete findings of this survey.
| PATIENTS AND METHODS
This study was conducted in 54 hospitals or clinics in Osaka Prefecture.
Each clinic was in charge of 10-30 postcards, depending on the capacity of their institution. A total of 1000 postcards was prepared for delivery. Patients were diagnosed using rapid influenza diagnostic tests, and neuraminidase inhibitors were prescribed between December 2012
and April 2013. After informed consent was obtained from the patient, the doctors wrote the patient's age, gender, influenza type (A or B), and drug details on the front page and provided the postcard to the patient.
The patients answered questions regarding their flu vaccination status, symptoms, temperature (twice daily), and drug-related adverse events and then posted the postcards to Osaka City University. The symptoms they reported included their highest temperature (recorded twice daily, in the morning and in the evening), sore throat, fatigue, headache, runny nose, and joint pain. A sample postcard is shown in Figure 1 .
Most published studies have reported the effectiveness of neuraminidase inhibitors. 3 Although the criterion for absence of fever in most studies was a temperature under 37.5°C, 37.8°C, or 38°C, we defined the absence of fever as a temperature under 37.0°C, because anything above this temperature is considered fever in Japan.
This study was approved by the Ethics Committee of Osaka City University (Approval No. 2465).
| Statistical analysis
The statistical analyzes were performed using JMP version 10 (SAS followed by a multivariate analysis with logistic regression models to examine the factors that were related to the alleviation of fever within 2 days after the treatment with the neuraminidase inhibitors began.
| RESULTS
Of the 863 postcards that were delivered, 263 were returned.
We compared the demographic data between the neuraminidase 
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inhibitors (Table 1) . Regarding age, there were significant differences among the neuraminidase inhibitors, except laninamivir vs peramivir.
The patients who were prescribed laninamivir and peramivir were older (mainly older than 10 years), whereas oseltamivir and zanamivir were prescribed to younger patients (mainly younger than 9 years).
Fewer patients prescribed laninamivir were infected in the previous year than were those prescribed oseltamivir and zanamivir. Moreover, fewer patients prescribed laninamivir were vaccinated this year than were those prescribed zanamivir, because the patients prescribed laninamivir were older and mostly adults who have lower infection and vaccination rates than children. 4 Laninamivir resulted in significantly fewer adverse events than oseltamivir. There were no significant differences in sex, influenza type (A or B), vaccination during the previous year, or risk factors. as shown in Table 1 . These results indicate that laninamivir was preferred for adults and oseltamivir was preferred for children. The use of oseltamivir, expressed as a proportion of all neuraminidase inhibitors, did not change over the 3 years. Peramivir was prescribed for a small proportion of patients, because all of the patients were treated in outpatient clinics for infections that were not considered severe.
| Consistent increase in the use of laninamivir

| Neuraminidase inhibitors had similar effects on influenza infections
The time taken to alleviate fever did not differ according to which neuraminidase inhibitor was used. Although peramivir helped resolve the fever earlier, the difference was not significant (P=.59). There were no significant differences in the duration of any other symptoms among the neuraminidase inhibitors (P=.70) (Figure 3 ).
| Effect of influenza virus type on the alleviation of fever 2 days after neuraminidase inhibitor treatment
The percentages of all patients with a high fever (>37.0°C) according to vaccination status are shown in Figure 4 . The fever duration was significantly longer in vaccinated influenza patients during the 2012-2013 season (P=.04). 
T A B L E 1 Characteristics and clinical feature of patients, compared between the 4 four neuraminidase inhibitors
| DISCUSSION
This study revealed the current usage and no significant difference of effectiveness of neuraminidase inhibitors and its effectiveness, and also only influenza virus type was related to the alleviation of fever within 2 days. We found that the only factor affecting the alleviation of fever within 2 days after starting treatment with a Upon the onset of influenza, fever or other symptoms of vaccinated patients may be equivalent to those of nonvaccinated patients. They might be the reasons for that vaccination did not shorten the duration of fever in this survey.
Regarding the prescribed drugs, the proportion of laninamivir prescriptions consistently increased. Laninamivir is a drug that is inhaled just once. Its effects and adverse events are similar to those of other neuraminidase inhibitors, and it is also very convenient for patients, which may lead to high compliance. Laninamivir was released in Japan and several Asian countries in 2010, but it is not available in other countries. Oseltamivir tended to be prescribed to patients younger than 9 years, and laninamivir was prescribed more frequently to patients older than 10 years. Small children, especially those younger than 3 years, have difficulty inhaling laninamivir. Because oseltamivir is orally administered, it is preferred for children. However, most
Percentage of patients with a high fever (>37.0°C) according to which neuraminidase inhibitor was prescribed. There were no significant differences between the groups. (Right) Length of time required to alleviate all of the symptoms according to which neuraminidase inhibitor was prescribed. There were no significant differences between the groups All of the medications were prescribed in outpatient clinics for patients with less severe influenza infection; therefore, peramivir was prescribed to only a few patients because it is used to prevent the spread of influenza infection in clinics or hospitals during long hospital stays, and it should be infused via an intravenous drip for longer than 15 minutes. However, peramivir can also be used for more severe infections in patients who need to receive mechanical ventilation.
The National Institute of Infectious Diseases of Japan reported that influenza drug resistance was not observed during the 2012-2013
season. 9 Before the 2009 pandemic, the A/H1N1 virus was almost entirely resistant to oseltamivir. 10 The 2009 pandemic erased this resistance to oseltamivir. Conducting this survey every year helps us to understand the effectiveness of anti-influenza drugs.
We used a postcard-based questionnaire in this study. laninamivir, and 2% peramivir, similar to our findings: 45% oseltamivir, 12% zanamivir, 39% laninamivir, and 4% peramivir. Therefore, the population of this survey might be representative suggesting the reliability of our data.
Although it is easy to perform this postcard survey and results in a low burden for doctors and patients, two biases and two limitations exist. The first bias is a doctor's bias. Doctors deciding which neuraminidase inhibitor to prescribe could lead to a prescription bias.
We reported previously that there were no significant differences in sex, age distribution, or choice of prescribed drugs between our survey and the Japan Physicians Association report, which is one of the most reliable investigations of influenza in Japan. 12 Our findings are relevant to the clinical setting. In this survey, oseltamivir and zanamivir were prescribed to young patients, mainly younger than 9 years. Because there are many child influenza patients every year, vaccination is recommended. 4 The patients who received oseltamivir and zanamivir may represent patients who were vaccinated during the same year or who were infected with the influenza virus during the previous year. The second bias is a patient's bias regarding adverse events. Laninamivir resulted in fewer adverse events than other drugs; however, it was difficult to determine the accuracy of these data because the reports depended on the patients' judgment. The patients may have included influenza symptoms as adverse events or vice versa. The first limitation is the list of symptoms. Although cough is a common symptom of influenza, we assessed the symptoms of fever, sore throat, fatigue, headache, runny nose, and joint pain.
For influenza patients, high fever and joint pain are the most common symptoms and were included in this study. The second limitation does not know the time of onset of influenza. We searched durations of fever after visiting hospitals or clinics; however, we did not show the onset of influenza. Kawai et al. reported the duration of fever depends on the when the first dose of oseltamivir is administered and not on the onset. They categorized the patients using oseltamivir into four groups on the basis of time from the onset of fever to the start of treatment (0-12, 13-24, 25-36, and 37-48 hours). The time to alleviate fever was similar in each group. 13 
| CONCLUSION
There were no significant differences of effects on fever and symptoms among neuraminidase inhibitors. Virus type was only related to the alleviation of fever.
